Gene - Diet Interactions

Insulin Sensitivity Clinical Trial

— Genediet  

Official title:

Gene-diet Interactions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01274091
• Other study ID #: 28//2010
• Status: Completed
• Phase: N/A
• First received: January 10, 2011
• Last updated: April 16, 2012
• Start date: August 2010
• Est. completion date: December 2011

Study information

• Verified date: April 2012
• Source: University of Eastern Finland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Interactions between genes and environment, i.e. our inherited responses to environmental changes, may be crucial in the development of the common diseases. The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect on seems to depend on intervention and age. In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene.

Aim of the study:

To test if subjects with Pro12Pro and Ala12Ala genotypes respond differentially to a diet supplemented with high saturated (SAFA) or polyunsaturated fat (PUFA).

Hypotheses:

1. Specific: Subjects with the Ala12Ala genotype will be more sensitive to dietary modification, and therefore respond more favorably to PUFA diet

2. More general: Dietary instructions individually tailored according to the genotype would allow better treatment of obesity and diabetes

Description:

Obesity and type 2 diabetes are increasing in all western countries, including Finland. Recent genome wide analyses have found > 30 genes that contribute to either condition.. However, none of these genes explain >5% of the disease risk and altogether they explain < 10% of the total disease risk in cross-sectional studies. Therefore, diet and physical activity are still the major determinants of the risk, as demonstrated by our earlier intervention studies in order to find out the effect of different dietary modifications on glucose and lipid metabolism. More importantly, interactions between genes and environment, i.e. our inherited responses to environmental changes, may be crucial in the development of the common diseases. Unfortunately, gene-environment interaction can only be effectively investigated in intervention studies that are more expensive than cross-sectional population screenings. This leads to a lower sample size and reduced power to detect effects of minor alleles. Despite these limitations the investigators have been able to demonstrate gene-intervention interactions for several genes, including PPARG, in the Finnish Diabetes Prevention study. There is an urgent need for studies investigating effects of tailored diets in individuals selected based on their genotype. This will be the next essential step leading to improved dietary treatments guided by genetic information.

The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect on seems to depend on intervention and age. Based on these findings the investigators created in collaboration with Johan Auwerx an Pro12Ala animal model that demonstrated a differential effect of dietary fat composition depending on the genotype. However, an important conclusive proof that subjects selected based on their Pro12Ala genotype would respond differently to specifically tailored diet modification is still needed.

In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene. As a primary endpoint the investigators expect insulin sensitivity to alter differently depending on the genotype. Additionally, a detailed characterization of energy, glucose and lipid metabolism will be performed. Because PPARG gene plays a central role in adipogenesis one of the aims of this study is to find new pathways, genes and gene clusters that are regulated by PPARG in humans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• BMI >20kg/m2 <29kg/m2

• Pro12Pro and Ala12Ala genotypes of PPARG Pro12Ala polymorphism

• participation to METSIM-study (METabolic Syndrome in Men, currently >10000 men included from the population living in Kuopio, principal investigator Markku Laakso)

• normoglycemia

Exclusion Criteria:

• type 2 diabetes

• other chronic diseases

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Insulin Resistance
• Insulin Sensitivity

Intervention

Other:
• PUFA-diet
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
• SAFA-diet
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.

Locations

Country	Name	City	State
Finland	University of Eastern Finland	Kuopio

Sponsors (2)

Lead Sponsor	Collaborator
Marjukka Kolehmainen	Kuopio University Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	insulin sensitivity	insulin sensitivity measured by oral glucose tolerance test at the beginning of the first, randomised diet	week 0	No
Primary	insulin sensitivity	insulin sensitivty measured by oral glucose tolerance test after the first diet	week 8	No
Primary	insulin sensitivity	Insulin sensitivity measured by oral glucose tolerance test in the beginning of the second, randomised diet	week 10	No
Primary	insulin sensitivity	insulin sensitivity measured by oral glucose tolerance test after the second diet	week 18	No
Secondary	peripheral blood mononuclear cell gene expression		week 8	No
Secondary	peripheral blood mononuclear cell gene expression		week 18	No
Secondary	serum lipids	serum lipids, including serum lipidomics and fatty acid composition	week 8	No
Secondary	serum lipids	serum lipids, including serum lipidomics and fatty acid composition	week 18	No
Secondary	inflammation	inflammation measured as serum cytokines and adipose tissue inflammation	week 8	No
Secondary	inflammation	inflammation measured as serum cytokines and adipose tissue inflammation	week 18	No
Secondary	energy expenditure	energy expenditure and the rates of substrate oxidation	week 8	No
Secondary	energy expenditure	energy expenditure and the rates of substrate oxidation	week 18	No
Secondary	insulin secretion		week 8	No
Secondary	insulin secretion		week 18	No
Secondary	adipose tissue gene expression		week 8	No
Secondary	adipose tissue gene expression		week 18	No